Loncom Pharma's Osimertinib Mesylate APIs are revolutionary in treating non-small cell lung cancer with specific genetic markers. These APIs selectively inhibit EGFR mutations, offering patients a targeted therapy that can lead to better outcomes and a reduced side effect profile.
